Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
OCU-410ST by Ocugen for Juvenile Macular Degeneration (Stargardt Disease): Likelihood of Approval
OCU-410ST is under clinical development by Ocugen and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to...